Mesoblast Limited

A$2.03As of Sun 8 Nov 2026, 12:00 UTC
ASX:MSBHealthcare
Country Australia
PE (Fwd) •••
TSR 10Y CAGR 5.84%
Div yield —
ROE (9.86%)
Biotechnology
Beta (5Y) 0.91
PE TTM —
TSR TTM (19.12%)
Mkt cap A$2.636B
ROIC (4.51%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$2.23
9.74%
98.18%
Sell 0|7|4|10|10
2Q26
3Q26
4Q26
1Q27
Earnings per share$
0.04
0.04
0.04
0.04
33.88%
23.27%
9.90%
14.84%
Revenue$M
152.1
158.4
156.9
153.2
3.13%
1.94%
0.02%
(1.36%)
Peers (US$1.810B)
Cap (US$)
PE
1.779B
—
Capital
TTM
5Y
10Y
Leveragex
1.423
(0.239)
(0.215)
EBIT/Intx
7.705
0.271
0.247
Own earn%
29.25
(7.80)
(9.32)
Sh yield%
31.92
20.00
19.72
Owners
Insiders/Inst%
10.11
66.34
Short interest%
3.39
SBC / revenue%
5.20
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
11
Op margin range%
28–32
$1 testx
0.0
Incr. ROIC%
11